AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
November 05, 2021- The 24-week integrated results from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluated the efficacy and safety of risankizumab (SKYRIZI®) versus placebo for the treatment of active psoriatic arthritis (PsA)¹
-
November 04, 2021- Nearly 30 abstracts on five investigational and approved medicines across eight cancer types to be presented at the 63rd ASH Annual Congress
-
November 01, 2021- Thirty-eight abstracts underscore AbbVie's commitment to advancing its portfolio of medicines to help more people living with rheumatic diseases
-
October 29, 2021- Presbyopia, or age-related blurry near vision, is a common, progressive condition that reduces the eye's ability to focus on near objects, affecting most adults over the age 40
-
October 29, 2021- In a Phase 3 clinical trial, Study 3111-301-001, cariprazine (VRAYLAR®) met its primary endpoint demonstrating statistically significant change from baseline to week six in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score in patients with major depressive disorder
-
October 29, 2021- Reports Third-Quarter Diluted EPS of $1.78 on a GAAP Basis, an Increase of 38.0 Percent; Adjusted Diluted EPS of $3.33, an Increase of 17.7 Percent
-
October 28, 2021-- The pivotal Phase 3, randomized, double-blind, double-dummy, active-controlled study of continuous, subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) in patients with advanced Parkinson's disease met its primary endpoint in a 12-week study
-
October 26, 2021- Detailed analyses to showcase visual outcomes and patient experience
-
October 15, 2021- CHMP positive opinion is based on data from two Phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2[1],[2]
-
October 11, 2021THE POWER OF YOU CAMPAIGN ADVOCATES FOR AWARENESS AND EMPOWERS CONFIDENCE
-
October 07, 2021- In Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial, upadacitinib (RINVOQ®) met the primary endpoint of ASAS40 at week 14 versus placebo (45 percent compared to 23 percent)[1]
-
October 07, 2021- In Study 1 of the Phase 3 SELECT-AXIS 2 clinical trial, RINVOQ® (upadacitinib) met the primary endpoint of ASAS40 at week 14 versus placebo (45 percent compared to 18 percent) in patients with ankylosing spondylitis and inadequate response to bDMARD therapy[1]
-
October 05, 2021
-
September 30, 2021- Analyses include long-term efficacy and safety data from the open-label extension period of KEEPsAKE-1 and KEEPsAKE-2 evaluating risankizumab in psoriatic arthritis[1]
-
September 30, 2021- New RINVOQ (upadacitinib) analysis from the pivotal Phase 3 atopic dermatitis clinical program shows consistent EASI 75 rates for RINVOQ across key baseline characteristics of adults and adolescents with moderate to severe atopic dermatitis at week 16[1]
-
September 28, 2021- QULIPTA demonstrated statistically significant, clinically meaningful rapid and continuous reductions in mean monthly migraine days among adults with episodic migraine compared to placebo across the 12-week treatment period with significant reductions seen in weeks 1-4¹
-
September 23, 2021- New analyses will highlight head-to-head trial evaluating safety and efficacy of RINVOQ® (upadacitinib) versus dupilumab in specific body regions of patients with moderate to severe atopic dermatitis
-
September 20, 2021- In three pivotal Phase 3 studies, risankizumab-rzaa demonstrated significant improvements in clinical remission and endoscopic response as both induction and maintenance therapy[1],[2],[3]
-
September 16, 2021- Significantly more upadacitinib patients achieved the primary and all secondary endpoints compared to placebo in Phase 3 induction and maintenance studies supporting the submissions[1-3]
-
September 13, 2021- AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise
-
September 10, 2021
-
September 10, 2021--Final results from PROviDE, a long-term, real-world study, evaluating the effectiveness of DUODOPA® (levodopa-carbidopa intestinal gel) in patients with advanced Parkinson's disease
-
September 09, 2021
-
September 09, 2021- Phase 1/2 first-in-human (FIH) dose escalation and cohort expansion trial evaluating safety and preliminary efficacy of epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) published in The Lancet
-
September 08, 2021--Results from an open-label, multicenter extension to the pivotal Phase 3 ADVANCE trial evaluate the safety and tolerability of oral atogepant for the preventive treatment of migraine
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
